ID   Mel-RMu/DR8
AC   CVCL_T020
SY   MelRMu DR8; Mel-RMU-DR8
DR   cancercelllines; CVCL_T020
DR   Cosmic; 1941946
DR   Wikidata; Q54905134
RX   PubMed=22437314;
CC   Selected for resistance to: ChEBI; CHEBI_75045; Dabrafenib (Tafinlar; GSK2118436).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_S994 ! Mel-RMu
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 16
//
RX   PubMed=22437314; DOI=10.1038/jid.2012.63;
RA   Gowrishankar K., Snoyman S., Pupo G.M., Becker T.M., Kefford R.F.,
RA   Rizos H.;
RT   "Acquired resistance to BRAF inhibition can confer cross-resistance to
RT   combined BRAF/MEK inhibition.";
RL   J. Invest. Dermatol. 132:1850-1859(2012).
//